Saumini Srinivasan

Saumini Srinivasan

Auto-generated profile, based on publicly available information

Saumini Srinivasan

Division of Pediatric Pulmonology CS Mott Children's Hospital, University of Michigan Ann Arbor Michigan USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2024 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
SSShivanthan Shanthikumar
Shivanthan Shanthikumar
WGWilliam A. Gower
William A. Gower
SSSaumini Srinivasan
Saumini Srinivasan
JRJonathan H. Rayment
Jonathan H. Rayment
PRPaul D Robinson
Paul D Robinson
SGSamuel Goldfarb
Samuel Goldfarb
Background: Many children undergo allogeneic hematopoietic stem cell transplantation (HSCT) for the treatment of malignant and nonmalignant conditions. Unfortunately, pulmonary complications occur frequently post-HSCT, with bronchiolitis obliterans syndrome (BOS) being the most common noninfectious pulmonary complication. Current international guidelines contain conflicting recommendations regarding post-HSCT surveillance for BOS, and a recent NIH workshop highlighted the need for a standardized approach to post-HSCT monitoring. As such, this guideline provides an evidence-based approach to detection of post-HSCT BOS in children. Methods: A multinational, multidisciplinary panel of experts identified six questions regarding surveillance for, and evaluation of, post-HSCT BOS in children. A systematic review of the literature was undertaken to answer each question. The Grading of Recommendations, Assessment, Development, and Evaluation approach was used to rate the quality of evidence and the strength of recommendations. Results: The panel members considered the strength of each recommendation and evaluated the benefits and risks of applying the intervention. In formulating the recommendations, the panel considered patient and caregiver values, the cost of care, and feasibility. Recommendations addressing the role of screening pulmonary function testing and diagnostic tests in children with suspected post-HSCT BOS were made. Following a Delphi process, new diagnostic criteria for pediatric post-HSCT BOS were also proposed. Conclusions: This document provides an evidence-based approach to the detection of post-HSCT BOS in children while also highlighting considerations for the implementation of each recommendation. Further, the document describes important areas for future research.

31 August 2023 in medRxiv
Verified
Preprint
Open access
PDF file
Maria OtthMaria Otth
Maria Otth
RKRahel Kasteler
Rahel Kasteler
RMRenée L. Mulder
Renée L. Mulder
JAJennifer Agrusa
Jennifer Agrusa
SASaro H. Armenian
Saro H. Armenian
CKClaudia E. Kuehni
Claudia E. Kuehni
Childhood, adolescent, and young adult (CAYA) cancer survivors are at risk of pulmonary dysfunction. Current follow-up care guidelines are discordant. Therefore, the International Late Effects of Childhood Cancer Guideline Harmonization Group established and convened a panel of 33 experts to develop evidence-based surveillance guidelines. We critically reviewed available evidence regarding risk factors for pulmonary dysfunction, types of pulmonary function testing, and timings of surveillance, then we formulated our recommendations. We recommend that CAYA cancer survivors and healthcare providers are aware of reduced pulmonary function risks and pay vigilant attention to potential symptoms of pulmonary dysfunction, especially among survivors treated with allogeneic haematopoietic stem cell transplantation, thoracic radiotherapy, and thoracic surgery. Based on existing limited evidence, our panel currently recommends pulmonary function testing only for symptomatic survivors. Since scarce existing evidence informs our recommendation, we highlight the need for prospective collaborative studies to address pulmonary function knowledge gaps among CAYA cancer survivors.

25 September 2026 in Pediatric Transplantation
Verified
Journal Article
Open access
PDF file
SPSapna A. Pardasani
Sapna A. Pardasani
ASAli Y. Suliman
Ali Y. Suliman
JFJose Amadeo Ferrolino
Jose Amadeo Ferrolino
RDRonald H. Dallas
Ronald H. Dallas
MPMegan Peterson
Megan Peterson
Diego Raul HijanoDiego Raul Hijano
Diego Raul Hijano
Background: Respiratory viral infections (RVIs) in allogeneic hematopoietic cell transplant (allo‐HCT) recipients can cause airflow obstruction (AFO). Despite this risk, the impact of community‐acquired RVI on PFTs in pediatric patients after allo‐HCT remains unclear. Objective: The study determines the role of RVI in the development of AFO post‐transplant among survivors of allo‐HCT. Study Design: This retrospective study analyzed St. Jude patients undergoing allo‐HCT between 2003–2020. AFO was defined by z ‐scores and forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio expressed as lower limit of normal (LLN). Baseline parameters were obtained before allo‐HCT, and Year 1 parameters within 425 days post allo‐HCT. Spirometry measures were calculated using the global lung function Initiative (GLI) calculator. Bivariate and multivariate logistic regression identified risk factors for AFO following allo‐HCT. Results: A total of 397 patients were included, with a median age of 12.7 years. RVI occurred in 13% of patients within the first 100 days after transplantation. AFO developed in 12% of patients. Among those with AFO, 68% had a baseline FEV1/FVC ratio above the LLN, and 11% had a history of lower respiratory tract infection (LRTI) ( p < 0.05). The median time from transplant to RVI was shorter in patients with AFO (12 vs. 34 days). A baseline LLN value was a significant predictor of AFO. However, after adjusting for known covariates, RVI was not independently associated with AFO risk. Conclusion: RVIs within 100 days of allo‐HCT did not significantly affect AFO following transplant in pediatric patients.